Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [December 2016]

Product Code:
596200600
Publication Date:
December 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF). Topics covered include expert opinions on the two Phase II adjunctive studies being conducted by Roche that are evaluating sildenafil or lebrikizumab added to pirfenidone. KOLs also weigh in on novel drugs that are in Phase II development, such as Afimmune’s DS102, an oral formulation of 15-hydroxyeicosapentaenoic acid (15-HEPE), Relief Therapeutics’ inhaled formulation of interferon (IFN)-gamma and Kadmon Corporation’s Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, KD025.

Business Questions:

  • How do the KOLs view Roche’s two adjunctive studies of pirfenidone with sildenafil or lebrikizumab and what are their expectations?
  • What are expert opinions on the designs of the two adjunct studies?
  • How do KOLs feel about the use of pirfenidone as a backbone therapy in combinations?
  • Which combination strategies are KOLs most optimistic about in IPF?
  • What do the experts think about DS102’s mechanism of modulating collagen turnover and its potential future in IPF? 
  • Do KOLs have any concerns about the use of inhaled IFN-gamma in IPF and if so, what are they? 
  • How do KOLs view the inhibition of the ROCK2 pathway in IPF and what needs to be taken into consideration?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved